Loading clinical trials...

Lifestyle Intervention for Prevention of Gastric Neoplasm | Clinical Trials | Clareo Health

UNKNOWNNA

Lifestyle Intervention for Prevention of Gastric Neoplasm

Positive Lifestyle Interventions for the Prevention of Gastric Pre-cancer and Cancer Occurrences in Patients With Chronic Atrophy Gastritis and Reccurence of Gastric Cancer After Endoscopic Resection

NCT02679495•Shandong University

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether positive lifestyle interventions (diet modification and smoking cessation) are effective in the prevention of gastric pre-cancer and cancer occurrences and reccurence of gastric cancer after endoscopic resection.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•diagnosis of chronic atrophy gastritis proved by gastroscopy biopsy pathology or early gastric cancer patients who have recieved endoscopic resection
•have one or several bad lifestyle habits such as eating too much salt, eating too few fruits, smoking, drinking wine, and lack of sleep.

Exclusion Criteria

•patients who refuse to change lifestyle according to the trial plan

Locations (1)

Linyi People's Hospital affiliated to Shandong University

Linyi, Shandong, China

Key Dates

Start Date

March 12, 2015

Primary Completion Date

December 1, 2022

Completion Date

December 1, 2023

Last Updated

November 7, 2022

Enrollment

350

ESTIMATED participants

Conditions

Stomach Neoplasms

Interventions

Active measures of lifestyle modification

BEHAVIORAL

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

MesotheliomaNeoplasms+6 more

View study

RECRUITINGPHASE2

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

NCT06630130

Stomach Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Lifestyle Intervention for Prevention of Gastric Neoplasm

Inclusion Criteria

Exclusion Criteria

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy

Application of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.